This observation leads us to assume that in patients with advanced ovarian cancer, high expression of CD157 may confer resistance to cell death induced by the loss of adhesive supports, thus generating a subpopulation of viable, highly malignant cells that might account for a rapid tumor relapse. Here, BST1 is linked to ovarian cancer.